GDB-17
See the following -
The Collateral Benefits of India's Open Source Drug Discovery Programme
Priyanka Pulla | Forbes India | April 9, 2014
India's Open Source Drug Discovery programme is struggling for lack of expertise and a research ecosystem. However, the programme's real contribution may be the creation of just such an ecosystem Read More »
- Login to post comments